Amrutanjan Health Care Limited — Results, 15-05-2025: Integrated Filing- Financial

Amrutanjan Health Care Limited has announced a board meeting on May 15, 2025, approving the financial results for the quarter and half-year.

1) Revenue Performance: Total revenue for the year was INR 451.82 Cr, up 7.2% YoY from INR 421.23 Cr. Growth was mainly driven by the OTC Products segment (INR 290.03 Cr), supported by contributions from Women’s Hygiene and Beverages.

2) Profitability and EPS: Net profit increased 13% to INR 50.83 Cr from INR 44.97 Cr, with EPS rising to INR 17.58 from INR 15.50. Profit before tax grew 11.5% to INR 69.13 Cr. Margin improvement was attributed to effective cost controls and volume growth.

3) Operational Costs: Expenses rose to INR 400.36 Cr versus INR 375.63 Cr, largely due to increased stock-in-trade purchases (INR 123.18 Cr vs. 106.31 Cr) and higher employee benefits (INR 59.10 Cr vs. 47.69 Cr), reflecting business expansion. Advertising and selling costs increased moderately, underscoring sustained marketing efforts.

4) Key Metrics: OTC Products continue to be the key profit driver with segment PBT at INR 20.26 Cr, while Women’s Hygiene segment operated at a slight loss (INR -1.77 Cr). EBITDA remained healthy, benefiting from operational leverage.

5) Balance Sheet / Cash Flow Health: Cash reserves rose sharply to INR 101.55 Cr from INR 37.12 Cr due to strong operating cash flow of INR 50.90 Cr. Capital work-in-progress jumped to INR 16.20 Cr reflecting ongoing capex. Low debt levels (total liabilities INR 94.77 Cr vs equity INR 326.61 Cr) highlight solid financial footing.

6) Management Commentary / Strategic Outlook: The company aims to expand Women’s Hygiene and Beverages businesses while strengthening OTC market leadership, with continued brand investments and innovation fueling growth.

Final Takeaway: Amrutanjan’s consistent revenue growth, improved margins, and strong cash flow point to positive momentum. Diversification efforts enhance growth potential, making it an attractive stable consumer healthcare opportunity for retail investors focused on steady earnings progression.